explore -WSS

explore

author：comprehensive 2025-10-02 17:56:13 - browse：9

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Change Healthcare payments predicted restored March 15

WSS

NEJM study link tiny plastics in blood vessels to heart problems

Former medical device CEO who sold dummy, plastic parts convicted of fraud

UnitedHealth quietly bought dozens of outpatient centers

Can medical device makers keep up in the race to treat obesity?

Biden administration plans revamp of organ transplant system

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Wikipedia

explore

focus

Alkermes shareholders re

Eli Lilly’s Mounjaro succeeds in second weight

Medicare proposal to cover medical devices draws a mixed reaction

In his State of the Union, Biden takes clear aim at 'Big Pharma'

In age of alternative facts, a scholarly course on calling out crap

Biogen nominates mother of director’s child to replace him on board

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Anesthesiologist group: stop taking Ozempic before surgery

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

hotspot

Biogen nominates mother of director’s child to replace him on board

How to fix the rural physician shortage in the U.S.

Precocious puberty in girls comes with mental health risks

Can medical device makers keep up in the race to treat obesity?

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Timeline: Key moments in fight for gay rights

focus

entertainment

focus

knowledge